The ROS1ders Announces Recipients of 2024 ROS1+ Cancer Innovation Awards
Haryana Blog/10315093
Trending...
- Mauro Schnaidman named as Managing Director in Miami, Florida
- Experience Trembling Firsthand with the New AgeMan® Tremor Simulator
- Last Call - Submit Your Proposal for the 2025 OpenSSL Conference in Prague
SACRAMENTO, Calif. - HaryanaBlog -- The ROS1ders, a global group of patients and caregivers living with ROS1+ cancer, announced the recipients of the 2024 ROS1+ Cancer Innovation Award. Funds for the awards were raised through individual contributions to The ROS1ders by patients and supporters. Each award carries a one-year, $75,000 seed grant to fund high-risk, high-reward research projects in ROS1+ cancer.
The recipients of the 2024 ROS1+ Cancer Innovation Awards are:
More on Haryana Blog
About The ROS1ders
The ROS1ders is the largest global group of patients and family members living with ROS1+ cancer. It seeks to improve outcomes for all ROS1+ cancers through community, education, and research. Membership in their private Facebook group exceeds 2000 people from over 50 countries. The nonprofit is internationally recognized in the oncology and patient advocacy communities as experts in their disease. Its resources include a medically-vetted website and collaborations with international ROS1+ clinicians, researchers and industry. Please visit theros1ders.org to learn more.
About ROS1+ Cancer
More on Haryana Blog
The recipients of the 2024 ROS1+ Cancer Innovation Awards are:
- Monte Winslow, PhD, Dmitri A. Petrov, PhD and Joel Neal, MD, PhD, Stanford University School of Medicine – Towards precision medicine for oncogenic ROS1 fusion driven lung cancer
This project will create models of each known ROS1 fusion variant and investigate how they influence cancer development and treatment responses. - Jaime Schneider, MD, PhD, Massachusetts General Hospital – Identifying Metabolic Vulnerabilities in ROS1+ Lung Cancer
This project aims to shed light on metabolic pathways that may contribute to acquired resistance to treatments for ROS1+ cancer, with the goal of identifying new targets for treatments that may prevent or treat resistance mechanisms.
More on Haryana Blog
- Sploot Vets and DeepScan Launch Exclusive Regional U.S. Partnership to Bring Breakthrough Pet DNA Test to Market
- As Sober.Buzz Community Explodes It's Growth Globally it is Announcing "Spreading the Good BUZZ" Podcast Hosted by Josh Case Debuting July 7th
- Coming Soon: The Cottages at Powell Park Offer a Rare Blend of Charm, Convenience, and Community in Raleigh
- CredHub and All County Property Management Franchise Corp. Partner to Empower Franchisees with Rental Payment Credit Reporting Solutions
- Pregis Shares 2024 Sustainability Report Highlighting Progress in Circular Product Innovation, Emissions Accountability, and Global Impact
About The ROS1ders
The ROS1ders is the largest global group of patients and family members living with ROS1+ cancer. It seeks to improve outcomes for all ROS1+ cancers through community, education, and research. Membership in their private Facebook group exceeds 2000 people from over 50 countries. The nonprofit is internationally recognized in the oncology and patient advocacy communities as experts in their disease. Its resources include a medically-vetted website and collaborations with international ROS1+ clinicians, researchers and industry. Please visit theros1ders.org to learn more.
About ROS1+ Cancer
- ROS1+ cancer is relatively rare, occurring in just 1-2% of non-small cell lung cancer. The incidence is thought to be similar in other types of cancer.
- Biomarker testing for ROS1 fusions is recommended in guidelines for non-small cell lung cancer, but few other cancers, yet.
- Patients typically have adenocarcinoma NSCLC, a younger age than the average NSCLC patient, and no smoking history (a smoking history should not exclude patients from biomarker testing or targeted therapies).
- Oral targeted therapies are the recommended first-line treatment for metastatic ROS1+ NSCLC and have increased the survival of patients by years. However, these drugs eventually stop working due to acquired resistance. The mechanisms of resistance are not well understood.
More on Haryana Blog
- Initial Order Received from Vietnamese Maritime Security and Defense Services for Advanced Video Compression Solution: RMX; Stock Symbol: RMXI
- Keebos Launches New Universal Pearl Strap That Attaches to Any Phone Case
- Work 365 Launches Certified Provider Integration (CPI) Program to Help Distributors and CSPs Navigate Microsoft's Evolving Ecosystem
- Five Aster Awards! Fusion Marketing Group Brings Home Big Wins in 2025!
- AI changes cryptocurrency market trading, TWL Miner launches new 1-day contract, giving away over $1 million
Source: The ROS1ders, Inc.
0 Comments
Latest on Haryana Blog
- Edtech Startup Young Commanders Launches 'Visionaries Without Sight' Collection Celebrating Blind and Visually Impaired Historical Figures
- Goldstar Rehabilitation Celebrates 15 Years of Early Intervention Across Southeastern PA
- United States Congressional Candidate Peter Coe Verbica Unveils 25-Point Federal Plan to Help Make California Affordable Again
- D8Averse Launches D8Acapture: Disruptive Mobile-First App Transforms Utility Pole Data Collection
- Experience Trembling Firsthand with the New AgeMan® Tremor Simulator
- Mauro Schnaidman named as Managing Director in Miami, Florida
- Continued Streak of Recognitions with Multiple Chambers and Partners Rankings
- Anern Shines at SOLAR AFRICA Kenya with Solar Lithium Battery Storage Technology
- Last Call - Submit Your Proposal for the 2025 OpenSSL Conference in Prague
- Robert Michael & Co. Launches New Real Estate Website to Serve Central Florida Homebuyers and Sellers
- IFFA 2025 Shines Bright as Mukesh Modi Welcomes Rio Rocket and Award Winner Lulu Lopez
- Kemeny, Ramp & Renaud Expands Legal Team with Attorney Baruch Kraut
- WOA Entertainment Group Unveils Independent No.1's: Breakthrough Artists II —A Celebration of Indie Excellence
- SheepFeast Launches "1 Million Discipled" Global Initiative to Empower Disciple-Making Around the World
- Sun City Resident Realtor Launches Exclusive Weekly Market Update for Bluffton's 55+ Communities!
- Delta Capital Group, Inc. Earns A+ Rating from the Better Business Bureau, Marking Another Milestone in Explosive Growth
- Vice President JD Vance & Industry Leaders at Bitcoin Conference After Partnership Signing to Optimize Cybersecurity Solutions: Bullet Blockchain, Inc
- Actress/Comedian Schelle Purcell Sizzles This Summer with Star-Making Turn in Tyler Perry's #1 Netflix Film, Straw, and Upcoming Comedy Special
- Braxus Entertainment Group Acquires All Star Events
- Global Expansion Fueled via Agreement to Take 90% Ownership of Nook Holdings UAE-Based Sports Incubator by Online Lottery & Sports Game Provider